Paragraph 16 Amendment of the Branded Health Service Medicines (Costs) Regulations 2018I1

United Kingdom

(1)

The Branded Health Service Medicines (Costs) Regulations 2018 M1 are amended as follows.

(2)

In regulation 1(2) (interpretation)—

F1(a)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(b)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(c)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(d)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(e)

in the definition of “supplementary protection certificate” omit from “means” to the end and insert “ has the meaning given by section 128B(2) of the Patents Act 1977 ”.

F2(3)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(4)

In regulation 9 (new presentation)—

(a)

in paragraph (10)—

F3(i)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F4(ii)

in sub-paragraph (b), after “Article 21” insert “or regulation 64(6) of the 2012 Regulations”; and

F5(b)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F6(5)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F7(6)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Annotations

Textual amendments

F1: Sch. 8 para. 16(2)(a)-(d) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(d)(i)
F2: Sch. 8 para. 16(3) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(d)(ii)
F3: Sch. 8 para. 16(4)(a)(i) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(d)(iii)
F4: Sch. 8 para. 16(4)(a)(ii) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(d)(iv)
F5: Sch. 8 para. 16(4)(b) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(d)(v)
F6: Sch. 8 para. 16(5) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(d)(vi)
F7: Sch. 8 para. 16(6) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(d)(vii)

Marginal citations

M1: S.I. 2018/345.

Commencement

I1: Sch. 8 para. 16 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1